Healthcare Author:Manyu Zhang Editor:Yiru Qian Apr 24, 2022 11:39 PM (GMT+8)

The funds will be used to build an ecosystem of the pharmaceutical service industry.

medicine

Dunen (Chinese:盾恩医学) recently received nearly CNY 100 million (USD 15.38 million) in the strategic financing round from CCIC Capital and other domestic investors. 

The proceedings will be used to develop a clinical precision medication platform and a precision medication database. Dunen also denoted that it planned to invest in the research and development of products related to pharmacogenetic testing and therapeutic drug monitoring, as well as a big data-backed medication guidance software and AI pharmacists.

Founded in 2017 and headquartered in Hangzhou, Zhejiang, Dunen is the landing unit of the "Precision Medication Research Center" affiliated to Yangtze Delta Region Research Institute of Tsinghua University. With a team of strong R&D capabilities, the company is committed to providing better and more reliable precision medication solutions for global medical experts and patients, and promoting the development of human health. 

“Dunen is currently an innovative biopharmaceutical enterprise with great development potential. With the back of this round of financing, we are confident to take the brand to a higher stage,” said Chen Zhijun, founder of Dunen.

Shao Xiangrong, deputy secretary of Yangtze Delta Region Research Institute of Tsinghua University, said: “We strongly endorse its presence in the pharmacy services industry and will continue to provide services like talent recruitment, training, and technical innovation for the company. We hope Duneen can become the next unicorn in this segment.” 

“Irrational medication is one of the great challenges facing the whole industry, which may result in poor treatment, and even death. We hope that Dunen would adhere to the its patient-centered philosophy, and constantly improve the level of pharmaceutical services,” said Professor Chen Shuqing from the School of Pharmacy, Zhejiang University.

Dunen’s competitors in the precision medication area include Hangzhou KBM Life sciences, Huizhong Bio, Zhunce Bio, Huidu Medical and GS Medical.